About ViaCell
ViaCell is a Healthcare company based in Cambridge (United States) founded in 1994, and was acquired by PerkinElmer in October 2007. It operates as a provider of services for collecting and preserving umbilical cord blood stem cells. ViaCell has raised $63 million across 2 funding rounds from investors including DWS, PerkinElmer and Nomura. Its focus areas include Life Sciences, Life Sciences Platforms and Tools, Research Services and Biorepository. Its competitors include GenVault Corporation, iSpecimen, Indivumed, BioStorage Technologies and AminoChain and 3 more; 6 of its 8 listed competitors have raised funding.
Company details
ViaCell is focused on the collection and preservation of umbilical cord blood stem cells. Its product ViaCord allows expectant families to preserve their babys umbilical cord blood at the time of birth and claims that it can be used for possible future medical use in treating over 40 life-threatening diseases, including certain leukemias, immune system deficiencies, and metabolic disorders. It also conducts RD to investigate potential therapeutic uses of umbilical cord blood-derived stem cells and address other maternal health needs.
- Headquarters Cambridge, United States
- Stage Acquired
- SectorsHealthcare
- Website viacellinc.com
- Acquired by PerkinElmer (Oct 2007)
- Total Equity Funding$63M (USD)
in 2 rounds
- Latest Funding Round$15M (USD), Private Equity Round
Nov 2001
- InvestorsDWS
& 3 more
- Acquired byPerkinElmer
(Oct 2007)
Funding Insights of ViaCell
ViaCell has successfully raised a total of $63M across 2 strategic funding rounds. The most recent funding activity was a Private Equity Round of $15 million completed in November 2001. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $63M
- Total Rounds 2
- Last Round Private Equity Round — $15M
- First Round $48M
(Nov 2000)
- Investors Count 3
All 2 funding rounds of ViaCell with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Nov 2001 | $15M | Private Equity Round | – | – | – |
| Nov 2000 | $48M | Private Equity Round | – | – |
4 investors in total: 4 institutional.
Investors in ViaCell
ViaCell has secured backing from 4 investors, including institutional and venture fund investors. Prominent investors backing the company include DWS, PerkinElmer and Nomura.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Private equity firm focused on multiple sectors | – | stephensgroup.com | Little Rock, United States | |
Asset management services are offered by DWS to clients. | 1956 | dws.com | Frankfurt, Germany | |
Diversified asset management services are offered globally by the firm. | 1925 | nomura.com | Chuo City, Japan | |
Medical instruments and supplies are manufactured and provided for healthcare. | 1931 | perkinelmer.com | Waltham, United States |
Investor details for ViaCell
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Timeline of ViaCell
5 dated milestones of ViaCell across 13 years, from founding to its latest funding, stage changes and deals.
- Founded ViaCell is founded.
- Funding First funding round of $48.0M.
- Funding Latest funding round, Private Equity Round, of $15.0M.
- IPO Lists on the stock exchange (IPO).
- Exit Acquired by PerkinElmer.
Competitors of ViaCell
ViaCell has 8 listed competitors in our database, 6 of them funded. They include GenVault Corporation, iSpecimen, Indivumed, BioStorage Technologies and AminoChain, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| genvault.com | 2000 | Carlsbad, United States | $47.8M | – | Biosamples are stabilized, transported, stored, and retrieved by GenVault. | |
| ispecimen.com | 2009 | Lexington, United States | $11.86M | 75 | Provider of a biorepository of human clinical specimens | |
| indivumed.com | 2002 | Hamburg, Germany | – | 178 | Biospecimens are collected, preserved, and analyzed for oncology services. | |
| biostorage.com | 2002 | Indianapolis, United States | $8.77M | – | Provides bio repository services | |
| aminochain.io | 2022 | New York, United States | $7.07M | – | A blockchain-based platform for tokenizing and incentivizing stem cell donations | |
| precisionmed.com | 1996 | San Diego, United States | – | – | Human biological materials for research are supplied via a biorepository. | |
| cryoniss.com | 2018 | Macclesfield, United Kingdom | $683,055 | 9 | Provider of biobanking services for life sciences industries | |
| biotransplant.org | 1990 | Boston, United States | $9.7M | – | Supplies tested tissues, allografts, and implantable tissue products for medical use. |
Detailed competitors of ViaCell
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of ViaCell
Websites that share an audience with ViaCell (viacellinc.com).
Websites whose visitors overlap most with ViaCell. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| cellresearchcorp.com | 100% | 1K | #15,245,759 | View details | |
| epistem.co.uk | 100% | 2.6K | #7,117,009 | View details | |
cxrbiosciences.com | cxrbiosciences.com | 100% | – | – | – |
isletmedical.com | isletmedical.com | 100% | – | – | – |
| cellerant.com | 100% | – | – | View details | |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 14 similar websites and full traffic analytics for ViaCell
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 14 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Top companies in Life Sciences Platforms & Tools
10 companies that operate in the same segment as ViaCell (Life Sciences Platforms & Tools), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Medidata is recognized as a leading provider of SaaS solutions for clinical research. | 1999 | New York, New York, United States | USD 41.5 M | – | – | |
AI-based solutions for health management are provided. | 2015 | Dallas, Texas, United States | USD 2.8 B | – | 1,111 | |
Nanopore-based electronic systems for single-molecule analysis are developed. | 2005 | Oxford, Oxfordshire, United Kingdom | USD 1.34 B | USD 301.49 M | 1,372 | |
Real-world health data is provided for research and decisions. | 2012 | Menlo Park, California, United States | USD 259.16 M | – | – | |
Genetically modified cell lines are developed using AAV gene-editing platform. | 2007 | Cambridge, Cambridgeshire, United Kingdom | USD 46.29 M | – | – | |
Biological reagents and antibodies are developed for life science research. | 1998 | Cambridge, Cambridgeshire, United Kingdom | USD 78.8 M | – | – | |
Electron microscopy services and microanalysis instruments are provided. | 1956 | Waltham, Massachusetts, United States | – | USD 44.56 B | 125,000 | |
Novel therapeutics are discovered using an AI-enabled drug platform. | 2013 | New York, New York, United States | USD 456.66 M | USD 74.68 M | – | |
A platform for sharing and accessing academic research papers is provided. | 2008 | San Francisco, California, United States | USD 58.4 M | – | – | |
Developer of molecular diagnostic testing solutions | 1996 | Sunnyvale, California, United States | USD 19.1 M | USD 54.88 M | 208 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about ViaCell
ViaCell was founded in 1994 and raised its 1st funding round 6 years after it was founded.
ViaCell is headquartered in Cambridge, United States. It is registered at Cambridge, Massachusetts, United States.
ViaCell is a funded company, having raised a total of $63M across 2 funding rounds to date. The company's 1st funding round was a Private Equity Round of $48M, raised on Nov 2000.
ViaCell is focused on the collection and preservation of umbilical cord blood stem cells. Its product ViaCord allows expectant families to preserve their babys umbilical cord blood at the time of birth and claims that it can be used for possible future medical use in treating over 40 life-threatening diseases, including certain leukemias, immune system deficiencies, and metabolic disorders. It also conducts RD to investigate potential therapeutic uses of umbilical cord blood-derived stem cells and address other maternal health needs.
ViaCell's top competitors include iSpecimen, AminoChain and GenVault Corporation.
ViaCell has 4 investors. Key investors include DWS, PerkinElmer, Nomura, and The Stephens Group.
Yes. ViaCell was acquired by PerkinElmer in October 2007.